Antimicrobial resistance: a class effect?

Antibiotic use has led to increased resistance to certain group markers: penicillin, erythromycin and ciprofloxacin for beta-lactams, macrolides and quinolones, respectively. The influence of resistance to markers in decreasing susceptibility to the drugs included (on the basis of chemical structure) in the corresponding antibiotic group can be defined as 'resistance class effect'. In the case of macrolides, this effect is dependent on the prevalent resistant phenotype among the isolates of the target bacteria: the class effect exists completely if the mechanism of resistance is constitutive MLS(B) (all macrolides are affected by resistance to erythromycin), and only partially if the mechanism is the efflux M phenotype (all but 16-membered macrolides are affected). In Spain, the first case is exemplified by Streptococcus pneumoniae and the second by Streptococcus pyogenes. For beta-lactams and quinolones, resistance to the group markers results in large decreases in the antimicrobial activity of the less potent members of the group, penicillin being a better driver of resistance for oral cephalosporins than for aminopenicillins, and ciprofloxacin being a better driver for older rather than for the newer quinolones, which have enhanced anti-pneumococcal activity. Empirical prescription guidelines based on the pharmacoepidemiology of resistance, recommending the use of potent drugs that are less influenced by resistance to the marker, may help to counter the spread of resistance in the community.

[1]  F. Baquero,et al.  Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997). , 2000, The Journal of antimicrobial chemotherapy.

[2]  P. Gilligan,et al.  Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  C. Cenjor,et al.  In Vivo Efficacies of Amoxicillin and Cefuroxime against Penicillin-Resistant Streptococcus pneumoniae in a Gerbil Model of Acute Otitis Media , 1998, Antimicrobial Agents and Chemotherapy.

[4]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[5]  T. File,et al.  Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. , 2002, The Journal of antimicrobial chemotherapy.

[6]  I. Jado,et al.  Short-Term Bactericidal Activity of Amoxicillin and Cefotaxime Against Penicillin-Susceptible and -Resistant Pneumococcal Strains: an In Vitro Pharmacodynamic Simulation , 2000, Journal of chemotherapy.

[7]  R. Dal-Ré,et al.  Activities against Streptococcus pneumoniae of amoxicillin and cefotaxime at physiological concentrations: in vitro pharmacodynamic simulation , 1996, Antimicrobial agents and chemotherapy.

[8]  F. Baquero,et al.  Antimicrobial Susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenesIsolates and Their Ecological Relationships: Results of a 1-Year (1998–1999) Multicenter Surveillance Study in Spain , 2001, Antimicrobial Agents and Chemotherapy.

[9]  I. Klinar,et al.  Azithromycin: 3-day versus 5-day course in the treatment of respiratory tract infections in children. Croatian Azithromycin Study Group. , 1997, Journal of chemotherapy.

[10]  F. Baquero,et al.  Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. , 2001, The Journal of antimicrobial chemotherapy.

[11]  M. Jones,et al.  Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998. , 2000, The Journal of antimicrobial chemotherapy.

[12]  D. Felmingham,et al.  The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. , 2000, The Journal of antimicrobial chemotherapy.

[13]  J. Yuste,et al.  Beta-lactam modification of the bacteraemic profile and its relationship with mortality in a pneumococcal mouse sepsis model. , 2002, The Journal of antimicrobial chemotherapy.

[14]  B. Aracil,et al.  High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998 , 2000 .

[15]  P. Empey,et al.  Levofloxacin Failure in a Patient with Pneumococcal Pneumonia , 2001, The Annals of pharmacotherapy.

[16]  M. A. Gerber Antibiotic resistance in group A streptococci. , 1995, Pediatric clinics of North America.

[17]  F. Dunstan,et al.  Antibiotic prescribing and antibiotic resistance in community practice: retrospective study, 1996-8 , 1999, BMJ.

[18]  G. Stefánsdóttir,et al.  Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study , 1996, BMJ.

[19]  J. Jeljaszewicz,et al.  Epidemiological aspects of antibiotic resistance in respiratory pathogens , 2001, International Journal of Antimicrobial Agents.

[20]  F. Baquero Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? , 1999, Journal of chemotherapy.

[21]  Á. Pascual,et al.  Differences between Two New Quinolones (Gemifloxacin and Trovafloxacin) and Ciprofloxacin in Their Concentration-Dependent Killing of Streptococcus pneumoniae , 2001, Chemotherapy.

[22]  F. Baquero,et al.  Influences of Different Factors on Prevalence of Ciprofloxacin Resistance in Streptococcus pneumoniae in Spain , 2000, Antimicrobial Agents and Chemotherapy.

[23]  E. Pérez-Trallero,et al.  Prediction of In-Vivo Efficacy by In-Vitro Early Bactericidal Activity with Oral β-lactams, in a Dose-Ranging Immunocompetent Mouse Sepsis Model, Using Strains of Streptococcus pneumoniae with Decreasing Susceptibilities to Penicillin , 2001, Journal of chemotherapy.

[24]  L. Aguilar,et al.  Does the degree of penicillin susceptibility of Streptococcus pneumoniae affect the bactericidal activity of co-amoxiclav versus oral cephalosporins at physiological concentrations? An in vitro pharmacodynamic simulation. , 1999, Journal of chemotherapy.

[25]  J. Oteo,et al.  Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study. , 2001, The Journal of antimicrobial chemotherapy.

[26]  R. Wise,et al.  The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone. , 1999, The Journal of antimicrobial chemotherapy.

[27]  C. Mcnulty Optimising antibiotic prescribing in primary care. , 2001, International journal of antimicrobial agents.

[28]  L. Aguilar,et al.  Pharmacodynamic effects of amoxicillin versus cefotaxime against penicillin-susceptible and penicillin-resistant pneumococcal strains: a phase I study , 1997, Antimicrobial agents and chemotherapy.

[29]  K. Coleman,et al.  In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens. , 2000, The Journal of antimicrobial chemotherapy.

[30]  J. Dorca,et al.  Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone. , 2001, Microbial drug resistance.

[31]  F. Marco,et al.  In Vitro Susceptibility to Gemifloxacin and Trovafloxacin of Streptococcus pneumoniae Strains Exhibiting Decreased Susceptibility to Ciprofloxacin , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[32]  F. Baquero,et al.  Importance of Local Variations in Antibiotic Consumption and Geographical Differences of Erythromycin and Penicillin Resistance in Streptococcus pneumoniae , 2002, Journal of Clinical Microbiology.

[33]  C. Cenjor,et al.  Role of Streptococcus pneumoniae and Haemophilus influenzae in the development of acute otitis media and otitis media with effusion in a gerbil model. , 2000, The Journal of infectious diseases.

[34]  F. Sörgel,et al.  Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. , 2001, International journal of antimicrobial agents.

[35]  M. Jones,et al.  Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. , 1999, The Journal of antimicrobial chemotherapy.

[36]  F. Baquero,et al.  Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997). , 2000, The Journal of antimicrobial chemotherapy.

[37]  J. Waitz Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .

[38]  W. Graninger,et al.  Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates. Austrian Bacterial Surveillance Network. , 1999, The Journal of antimicrobial chemotherapy.

[39]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[40]  L. Aguilar,et al.  Influence of the decrease in ciprofloxacin susceptibility and the presence of human serum on the in vitro susceptibility of Streptococcus pneumoniae to five new quinolones. , 2001, The Journal of antimicrobial chemotherapy.

[41]  F. Soriano,et al.  Correlation of in-vitro activity and pharmacokinetic parameters with in-vivo effect of amoxycillin, co-amoxiclav and cefotaxime in a murine model of pneumococcal pneumonia. , 1996, The Journal of antimicrobial chemotherapy.

[42]  G. Woodnutt Pharmacodynamics to combat resistance. , 2000, The Journal of antimicrobial chemotherapy.

[43]  D E Low,et al.  Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. , 1999, The New England journal of medicine.

[44]  G. Drusano,et al.  Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. , 1997, Journal of chemotherapy.

[45]  O. Cars,et al.  Control of antimicrobial resistance: time for action , 1998, BMJ.